Treatment Set TS343825 is a Intradermal; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Antigen Laboratories, Inc.. The primary component is Alternaria Alternata; Aspergillus Fumigatus; Cochliobolus Sativus; Cladosporium Cladosporioides; Penicillium Chrysogenum Var. Chrysogenum.
| Product ID | 49288-0824_bb49432e-682e-4b49-8a8e-a6f9eddd7bfc |
| NDC | 49288-0824 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Treatment Set TS343825 |
| Generic Name | Treatment Set Ts343825 |
| Dosage Form | Injection, Solution |
| Route of Administration | INTRADERMAL; SUBCUTANEOUS |
| Marketing Start Date | 1986-10-31 |
| Marketing Category | BLA / BLA |
| Application Number | BLA102223 |
| Labeler Name | Antigen Laboratories, Inc. |
| Substance Name | ALTERNARIA ALTERNATA; ASPERGILLUS FUMIGATUS; COCHLIOBOLUS SATIVUS; CLADOSPORIUM CLADOSPORIOIDES; PENICILLIUM CHRYSOGENUM VAR. CHRYSOGENUM |
| Active Ingredient Strength | 0 g/mL; g/mL; g/mL; g/mL; g/mL |
| Pharm Classes | Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS],Non-Standardized Fungal Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Fungal Proteins [CS],Allergens [CS] |
| NDC Exclude Flag | E |
| Listing Certified Through | 2017-12-31 |
| Marketing Start Date | 1986-10-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA102223 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 1986-10-31 |
| Inactivation Date | 2019-11-13 |
| Ingredient | Strength |
|---|---|
| ALTERNARIA ALTERNATA | .01 g/mL |